Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
FBXO9 Antibody (C-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q9UK97 |
|---|---|
| Other Accession | NP_036479.1 |
| Clone Names | 91009087 |
| Gene ID | 26268 |
|---|---|
| Other Names | F-box only protein 9, Cross-immune reaction antigen 1, Renal carcinoma antigen NY-REN-57, FBXO9, FBX9, VCIA1 |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | FBXO9 |
|---|---|
| Synonyms | FBX9, VCIA1 |
| Function | Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins and plays a role in several biological processes such as cell cycle, cell proliferation, or maintenance of chromosome stability (PubMed:34480022, PubMed:23263282). Ubiquitinates mTORC1-bound TTI1 and TELO2 when they are phosphorylated by CK2 following growth factor deprivation, leading to their degradation. In contrast, does not mediate ubiquitination of TTI1 and TELO2 when they are part of the mTORC2 complex. As a consequence, mTORC1 is inactivated to restrain cell growth and protein translation, while mTORC2 is the activated due to the relief of feedback inhibition by mTORC1 (PubMed:23263282). Plays a role in maintaining epithelial cell survival by regulating the turn- over of chromatin modulator PRMT4 through ubiquitination and degradation by the proteasomal pathway (PubMed:34480022). Regulates also PPARgamma stability by facilitating PPARgamma/PPARG ubiquitination and thereby plays a role in adipocyte differentiation (By similarity). |
| Cellular Location | Cytoplasm. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a member of the F-box protein familywhich is characterized by an approximately 40 amino acid motif, theF-box. The F-box proteins constitute one of the four subunits ofthe ubiquitin protein ligase complex called SCFs(SKP1-cullin-F-box), which function in phosphorylation-dependentubiquitination. The F-box proteins are divided into 3 classes: Fbwscontaining WD-40 domains, Fbls containing leucine-rich repeats, andFbxs containing either different protein-protein interactionmodules or no recognizable motifs. The protein encoded by this genebelongs to the Fbxs class. Alternative splicing of this genegenerates at least 3 transcript variants diverging at the 5'terminus.
References
Jin, J., et al. Genes Dev. 18(21):2573-2580(2004)Mungall, A.J., et al. Nature 425(6960):805-811(2003)Scanlan, M.J., et al. Int. J. Cancer 83(4):456-464(1999)Winston, J.T., et al. Curr. Biol. 9(20):1180-1182(1999)Cenciarelli, C., et al. Curr. Biol. 9(20):1177-1179(1999)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Shipping Information
